Highlights from TAT 13 in Rio de Janeiro

April 21, 2026

Highlights from TAT 13 in Rio de Janeiro

We’re excited to have been part of hashtag#TAT13 in Rio! It was a fantastic opportunity to connect with the community, exchange ideas, and see the field continuing to move forward at an impressive pace. One particularly exciting highlight was a very recent development pointing to the clinical potential of astatine-211, with early clear indications of..

Umberto Battisti Presenting at the AACR Annual Meeting 2026 in San Diego

April 14, 2026

Umberto Battisti Presenting at the AACR Annual Meeting 2026 in San Diego

We’re excited to share that our Co-founder and CSO Umberto Battisti will be presenting at the AACR Annual Meeting 2026 in San Diego! The poster, “Efficacy of targeted radionuclide therapy using ¹³¹I-FAPi dimers labeled via tetrazine ligation in a human glioblastoma xenograft model,” has been selected for presentation in the session Radiopharmaceutical Platforms for Theranostic..

Meet us in the Annual Danish Radiochemistry Meeting 2026

March 20, 2026

Meet us in the Annual Danish Radiochemistry Meeting 2026

Come and meet us in Copenhagen! TetraKit will be at the Annual Danish Radiochemistry Meeting 2026 from March 26 – 27. Matthias Herth, Andreas Ingemann Jensen, Umberto Maria Battisti and Dr. Marcel Martin from our team will be attending and would be happy to connect! 📧 matthias.herth@tetrakit.com📧 andreas.jensen@tetrakit.com📧 umberto.battisti@tetrakit.com📧 marcel.martin@tetrakit.com

We’re Heading to TAT 13 in Rio de Janeiro

March 18, 2026

We’re Heading to TAT 13 in Rio de Janeiro

Our Co-founder & COO Andreas Ingemann Jensen and Project & Business Developer Rocío García Vázquez will be attending the 13th International Symposium on Targeted Alpha Therapy (TAT 13) in Rio from April 14 – 16. At Tetrakit Technologies, we’re working with tetrazine-based click chemistry to enable fast and high-yield radiolabeling of any cancer-targeting biomolecule with..

Join us at the South Summit Brazil in Porto Alegre from March 25 – 27

March 17, 2026

Join us at the South Summit Brazil in Porto Alegre from March 25 – 27

Join us at the South Summit Brazil in Porto Alegre from March 25 – 27! This year is extra special for us as we’ll have our own booth at the event. If you’re attending, come by booth 30 and say hello to Rocío García Vázquez from the TetraKit team! We will be ready with TetraKit..

Darja Beyer presenting during the 21st ESMI Meeting in Ljubljana, Slovenia

March 13, 2026

Darja Beyer presenting during the 21st ESMI Meeting in Ljubljana, Slovenia

We’re happy to announce Darja Beyer will be presenting during the 21st European Society for Molecular Imaging – ESMI Meeting in Ljubljana, Slovenia🎉 At EMIM 2026, Darja will present a talk on how novel FAP-targeted radiopharmaceutical expands theranostic strategies beyond conventional radiometals. By using a click-based tetrazine ligation approach, [¹³¹I]I-DualFAPi-5 was efficiently synthesized with high..

Promising preclinical results for ¹³¹I-DualFAPi-5🎉

March 12, 2026

Promising preclinical results for ¹³¹I-DualFAPi-5🎉

We’re excited to share new preclinical biodistribution and efficacy data for ¹³¹I-DualFAPi-5, our FAPi dimer lead candidate labeled with iodine-131, here shown head to head against its close radiometal analog, ¹⁷⁷Lu-DOTAGA-Glu(FAPi)2. In this preclinical model, tumor uptake with ¹³¹I-DualFAPi-5 was approximately 3× higher, highlighting the strong potential of 1¹³¹I-DualFAPi-5 for effective FAP-targeted radioligand therapy, as well as..

World Cancer Day

February 4, 2026

World Cancer Day

February 4th marks World Cancer Day, a global reminder of the importance of awareness, prevention, and meaningful action against cancer. At Tetrakit Technologies, this mission aligns with our own. Through innovation and collaboration, we are developing next-generation therapeutic and diagnostic radiopharmaceutical assets to improve outcomes for cancer patients🔬

We are excited to welcome Darja Beyer to our team!

February 2, 2026

We are excited to welcome Darja Beyer to our team!

Darja will be joining us as a Senor Translational Scientist and will play a key role in advancing translational radiopharmaceutical research☢️ A warm welcome to our newest team member, Darja! She joins us with a strong background in Pharmaceutical Sciences and a PhD from the Paul Scherrer Institute, where she worked on the preclinical development..

Accelerate.EU consortium at TWC

January 30, 2026

Accelerate.EU consortium at TWC

Great to be at the Theranostics World Congress with the Accelerate.EU consortium.We are happy to share the progress made on Astatine-211 and targeted alpha therapies, and to highlight Antero Abrunhosa’s session today on the Accelerate.EU vision and roadmap for alpha innovation in Europe. If you are at TWC, come and meet us. We would be..

Updated website

January 28, 2026

Updated website

We’re pleased to share that our website has been updated! Visit tetrakit.com to learn about our growing pipeline and how the TetraKit Platform turns cancer-targeting biomolecules into radiopharmaceuticals labeled with astatine-211 and other radionuclides ☢️

Just one week to go! 🔬

January 22, 2026

Just one week to go! 🔬

The 8th Theranostics World Congress is just around the corner and we’re very excited to attend. During the congress, our CEO and Co-founder, Dr. Matthias Herth, will present a talk on halogenated FAPI theranostics featuring fluorine-18, iodine-123/131, and astatine-211 on Saturday, January 31st, from 15:30 to 17:00. If you haven’t already reached out and would..

TWC 2026

January 22, 2026

TWC 2026

Attending Theranostics World Congress ? Meet members of the Accelerate.EU consortium to discuss our progress in developing ²¹¹At-based alpha radiotheranostic. 📌 Poster presentation“Regulatory Challenges for Novel Alpha Therapies: A Call for Harmonization”Presented by Prof. Antero Abrunhosa. Participating institutions: IBA RadioPharma Solutions (François-Xavier Feltz), Erasmus MC (Yann Seimbille), Forschungszentrum Jülich (B. Neumaier), Københavns Universitet – University..

Happy Holidays!

December 22, 2025

Happy Holidays!

As the year comes to a close, we’re taking a moment to reflect on what has been an exciting and transformative year for TetraKit. From major funding milestones to scientific breakthroughs and team growth, 2025 has laid a strong foundation for what’s ahead. This year, we: – Were selected for the highly prestigious EIC Accelerator..

Join us for an exciting session!

December 11, 2025

Join us for an exciting session!

Our CEO and Co-founder, Dr. Matthias Herth, will present during the TME Diagnostics session at Theranostics World Congress on Saturday, January 31st, 2026, from 15:30-17:00. His presentation will cover halogenated FAPI theranostics featuring fluorine-18, iodine-123/131, and astatine-211. We look forward to welcoming everyone interested halogenated FAPI theranostics.

Theranostics World Congress (TWC)

December 4, 2025

Theranostics World Congress (TWC)

Are you attending the 8th Theranostics World Congress (TWC) in Cape Town, South Africa, from January 29th to February 1st, 2026? So is TetraKit! Our CEO & Co-Founder Matthias Herth and COO & Co-Founder Andreas Ingemann Jensen will be available throughout the congress. If you’re interested in discussing potential collaboration, feel free to reach out...

TetraKit had a great time attending NOAR

November 13, 2025

TetraKit had a great time attending NOAR

TetraKit had a great time attending the NOAR Europe annual meeting last week in Nantes! Nadia Bom Pedersen, Ph.D. Felllow, presented her research in a session that focused on comparing the various promising strategies to prevent in vivo deastatination and increase efficacy and safety in targeted alpha therapy with ²¹¹At. Andreas Ingemann Jensen, our co-founder and..

Nadia will present at NOAR

October 21, 2025

Nadia will present at NOAR

We’re excited to share that Nadia will present her astatine research at the NOAR Europe Annual Meeting during the Regular Academic Presentations & Hot Topics session (17:45–18:30) in Nantes, France👏 Her presentation, “Toward In Vivo Stability: A Comparative Study of ²¹¹At-Labeled Small Molecular Scaffolds” offers a systematic comparison of published strategies to minimize deastatination under..

Another exciting conference for TetraKit!

October 14, 2025

Another exciting conference for TetraKit!

This time, Matthias Herth and Andreas Ingemann Jensen will be attending the NOAR Europe Annual Meeting in Nantes, France from 3rd – 5th November 2025. We’re thrilled to explore the latest advances in targeted alpha therapy, especially astatine-211. Are you also attending? Make sure to reach out to either Matthias or Andreas, they’d be happy..

Last week TetraKit wrapped up an exciting time at EANM🎉

October 13, 2025

Last week TetraKit wrapped up an exciting time at EANM🎉

Dr. Marcel Martin presented recent advances in the radiosynthesis and preclinical evaluation of ¹⁸F-Flutrahexin radiolabeled via the TetraKit platform for αvβ6-positive tumors, such as pancreatic cancer. The 18F-labeled tracer performs on par with ⁶⁸Ga-Trivehexin and offers promising opportunities for high-resolution PET imaging and theranostic applications with ¹³¹I and ²¹¹At. The TetraKit team looks forward to..

TetraKit will be at the EANM

September 12, 2025

TetraKit will be at the EANM

We’re thrilled to share that TetraKit will be at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM), taking place in Barcelona, Spain from October 4–8, 2025. Matthias Herth (Co-founder & CEO), Andreas Ingemann Jensen (Co-founder & COO), Umberto Maria Battisti (Co-founder & CSO), Rocío García Vázquez (Project Manager) and Dr. Marcel Martin..

Leadership reshuffling at TetraKit Technologies

September 10, 2025

Leadership reshuffling at TetraKit Technologies

We’re excited to announce a leadership reshuffling at TetraKit Technologies. This change will support our continued growth as we move into the next phase of development🔬

Our radiochemistry laboratory has been fully operational since July

September 7, 2025

Our radiochemistry laboratory has been fully operational since July

We are excited to share that our radiochemistry laboratory has been fully operational since July 🎉 including work with astatine-211. This is a major achievement for the Department of Drug Design and Pharmacology, University of Copenhagen. A special thanks to Nadia Renée Bom Pedersen, Marius Müller, Marcel Martin and Umberto Battisti for their excellent work in establishing the radiochemistry..

TetraKit publishes a new review🎉🔬

September 3, 2025

TetraKit publishes a new review🎉🔬

A new review on astatine-211, first-authored by Marius Müller and Nadia Bom Pedersen and forged in the rapidly advancing astatine-211 research environment at the University of Copenhagen, under the guidance of Prof. Matthias Herth and Umberto Maria Battisti.

Nadia won the prize for best oral presentation along with 3 other PhD students🔬🎉

September 2, 2025

Nadia won the prize for best oral presentation along with 3 other PhD students🔬🎉

2 weeks ago Nadia Bom Pedersen presented her PhD project at the Drug Research Academy (DRA) summer school 2025 and won the prize for best oral presentation along with 3 other PhD students. Massive congratulations on this achievement and the excellent presentation of your research! 🔬🎉 Nadias PhD project focuses on astatine chemistry, with the..

We’re excited to announce Rune Wiik Kristensen as a member of TetraKit’s Board of Directors!🎉

August 28, 2025

We’re excited to announce Rune Wiik Kristensen as a member of TetraKit’s Board of Directors!🎉

Meet Rune, a member of TetraKit’s Board of Directors Rune Wiik Kristensen is a serial entrepreneur in the field of Nuclear Medicine and Radiopharmaceuticals, bringing with him more than a decade of C-suite level managerial experience in startup and scale up businesses. Having both co-founded MedTrace Pharma, a company dedicated to commercializing the use of..

Team day at Tetrakit!✨

August 26, 2025

Team day at Tetrakit!✨

Last Friday, our team came together for an all-hands meeting to share the latest company updates, discuss ongoing projects, and explore new initiatives across operations and R&D. The discussion included updates on our lead program, DualFAPi, along with advances in the initial ²¹¹At-radiolabeling of our TetraKit-based compounds. At TetraKit, we aim to advance next-generation radioligand..

TetraKit celebrates EIC Accelerator award together with Catalyze! ✨

August 14, 2025

TetraKit celebrates EIC Accelerator award together with Catalyze! ✨

Catalyze supported TetraKit in preparing our successful submission to the EIC Accelerator (October 2024 round). We were awarded blended financing to advance the clinical development of our lead asset, ¹³¹I-DualFAPi. Initially focused on metastasized Triple Negative Breast Cancer, this therapy has the potential to benefit a broad population of cancer patients worldwide. Full article by..

Discover how TetraKit contributes to Accelerate.EU

July 3, 2025

Discover how TetraKit contributes to Accelerate.EU

💬 “It’s a chicken-and-egg problem.” Andreas Ingemann Jensen, CEO of TetraKit Technologies explains how developing a breakthrough treatment with Astatine-211 requires building the drug and its supply chain at the same time. 📽️ In this short video, discover how TetraKit contributes to Accelerate.EU by pushing the boundaries of innovation in targeted alpha therapies. Full post..

TetraKit is attending the SNMMI 2025 Annual Meeting in New Orleans, Louisiana!

June 18, 2025

TetraKit is attending the SNMMI 2025 Annual Meeting in New Orleans, Louisiana!

We are excited to announce that Dr. Matthias Herth, along with Dr. Rocío García Vázquez, will be attending this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in New Orleans, Louisiana, from June 21–24, 2025. The SNMMI Annual Meeting is a premier event that brings together leading experts in nuclear medicine and..

Nadia received the AMTAR Poster Award in Australia🎉

May 21, 2025

Nadia received the AMTAR Poster Award in Australia🎉

We’re incredibly proud of Nadia Bom Pedersen for receiving the AMTAR Poster Award at this year’s iSRS25 in Australia – International Symposium on Radiopharmaceutical Sciences! This important event brings together researchers from around the world to share the latest advances in the radiopharmaceutical field. Nadia presented her research on “Small molecular scaffolds toward in vivo..

Strategic collaboration with 3B Pharmaceuticals

April 10, 2025

Strategic collaboration with 3B Pharmaceuticals

📣 TetraKit Technologies has entered into a strategic collaboration with 3B Pharmaceuticals to co-develop a targeted alpha therapy (TAT) using astatine-211. This partnership combines our TetraKit radiolabeling platform with 3BP’s deep expertise in drug discovery to advance a novel peptide radiopharmaceutical for oncology. The goal: to enable more effective cancer treatments through precision radiotherapy. We’re looking..

🚀 Eurostars Collaboration Officially Kicked Off in Uppsala!

April 3, 2025

🚀 Eurostars Collaboration Officially Kicked Off in Uppsala!

We’re excited to officially launch the PRE-CISE project, a Eurostars-funded collaboration between TetraKit Technologies, Akiram Therapeutics, and our Danish partners PreTT. At TetraKit Technologies, we bring cutting-edge radiolabeling technology and expertise in advanced radioligand therapies to this project. Together, we aim to push the boundaries of precision cancer treatment by developing next-generation pre-targeted radiotherapeutic alpha..

TetraKit is part of the AstraTATE project!

April 3, 2025

TetraKit is part of the AstraTATE project!

TetraKit is proud to be part of the AstraTATE project, supported by Innovationsfonden with a total investment of DKK 21.7 million. The project focuses on developing a novel radionuclide therapy for treating neuroendocrine tumors (NET), using the alpha-emitting isotope astatine-211 (At-211). The aim is to create a more targeted treatment approach that could reduce harm..

We’ve been selected for funding under the prestigious EUeic Accelerator!

February 19, 2025

We’ve been selected for funding under the prestigious EUeic Accelerator!

We are thrilled to share that we’ve been positively evaluated and selected for funding under the prestigious EUeic Accelerator! 🎉 Being part of this highly competitive round is a true honor, and we’re incredibly proud and thankful to European Innovation Council and SMEs Executive Agency (EISMEA) for this opportunity. A huge congratulations to the other..

Exciting innovation in oncology!

February 10, 2025

Exciting innovation in oncology!

Framatome Healthcare and IBA are joining forces to develop an Astatine-211 Cyclotron Network, enabling industrial-scale production of this promising radioisotope for targeted alpha therapy. With the pilot facility launching in France by 2027-2028, this marks a huge step in transforming cancer care. At Tetrakit Technologies, we’re inspired by this progress and remain committed to advancing..

New Eurostars grant

December 2, 2024

New Eurostars grant

🚀 Thrilled to announce our new Eurostars grant! We at TetraKit Technologies are excited to join Akiram Therapeutics and PreTT in receiving the prestigious Eurostars grant to advance groundbreaking cancer therapies using antibodies for radioligand therapy. A huge thanks to the full team for their incredible contributions. Stay tuned for updates on this exciting journey..

🔬 New Publication on the Astatination of Tetrazines

December 2, 2024

🔬 New Publication on the Astatination of Tetrazines

TetraKit team members have co-authored a new paper on the astatination of tetrazines, now published in Chemistry – A European Journal. We’re excited to share it with you! In this paper, they describe the synthesis and radiolabeling of various relevant tetrazine scaffolds using astatine-211. It’s open-access, so feel free to take a look! Want to..

Accelerate.EU program

October 25, 2024

Accelerate.EU program

Tetrakit is excited to be part of the Accelerate.EU program, joining 17 leading institutions across 9 countries to advance radiotheranostics and innovative cancer treatments. Together, we’re driving alpha therapy innovation in Europe. Stay tuned for more updates! Read the full article on our LinkedIn page: https://www.linkedin.com/feed/update/urn:li:activity:7255569123626131456

Wrapping up EANM 2024!

October 25, 2024

Wrapping up EANM 2024!

Wrapping up an inspiring week at European Association of Nuclear Medicine (EANM) 2024! Proud of the Tetrakit team’s contributions to the advancement of nuclear medicine: “Novel FAPi dimers labeled via tetrazine ligation” – Dr. Marcel Martin presented our latest research using the click chemistry-based TetraKit platform, focusing on radioligand therapy for FAPi dimers. “Pre-targeting Approach:..

TetraKit at the European Association of Nuclear Medicine (EANM) 2024

October 21, 2024

TetraKit at the European Association of Nuclear Medicine (EANM) 2024

The Tetrakit team is excited to be at European Association of Nuclear Medicine (EANM) in Hamburg! It’s been an incredible opportunity to connect, learn, and dive into the latest advancements in nuclear medicine. Looking forward to more great discussions!

Advancing cancer diagnostics! 🔬

October 8, 2024

Advancing cancer diagnostics! 🔬

We are proud to announce the successful completion of the first preclinical steps for 18F-Flutrahexin, a new fluorine-18 labeled PET tracer analog of 68Ga-Trivehexin, developed together with TRIMT GmbH. This innovation holds great promise for advancing the diagnostics of cancers like pancreatic, lung, head and neck, and ovarian cancers. In addition to diagnostics, 18F-Flutrahexin opens up new possibilities..

Accelerate.EU has been officially launched!

October 7, 2024

Accelerate.EU has been officially launched!

The Accelerate.EU has been officially launched with the ambitious goal of establishing a resilient and strategic European autonomy in alpha therapies. This collaboration brings together 17 leading European institutions and companies across 9 countries, blending academic expertise with industrial innovation. The project is coordinated by the Institut Jules Bordet and IBA RadioPharma SolutionsInstitut de Cancérologie..

Exciting milestone for TetraKit Technologies!

October 7, 2024

Exciting milestone for TetraKit Technologies!

We are thrilled to announce that TetraKit Technologies’ lead compound DualFAPi (a FAP-targeted dimer designed to prolong tumor residence) has been selected as one of three candidates for clinical evaluation under the prestigious Accelerate.EU initiative. This innovative €16 million project, funded by the Institute for Health Innovation (IHI), is a major step forward for our..

37th Annual Congress of the European Association of Nuclear Medicine (EANM) in Hamburg

September 5, 2024

37th Annual Congress of the European Association of Nuclear Medicine (EANM) in Hamburg

We are excited to announce that Dr. Marcel Martin, along with Rocío García Vázquez, Matthias Herth, Andreas Ingemann Jensen and Umberto Maria Battisti will be representing TetraKit Technologies at this year’s 37th Annual Congress of the European Association of Nuclear Medicine (EANM) in Hamburg! At TetraKit Technologies, we specialize in developing innovative theranostic compounds using..

CAFACHEM 2024

July 2, 2024

CAFACHEM 2024

We are excited to announce that our CSO, Prof. Matthias M. Herth, will be representing TetraKit Technologies as a Keynote Speaker at this year’s SRS Think Tank Summer School on Organic and Halogen Radiochemistry (CAFACHEM 2024). 🌟 At TetraKit Technologies, we specialize in the development of theranostic compounds using our innovative click chemistry-based TetraKit platform,..

Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024

July 2, 2024

Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024

Wrapping up an incredible experience at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference! It was a blast to meet so many amazing professionals, see the progress in the field of nuclear medicine and make new connections. 🚀 #SNMMI2024

7th Theranostics World Congress

March 18, 2024

7th Theranostics World Congress

We are thrilled to announce our participation in the upcoming 7th Theranostics World Congress, where our esteemed experts will be sharing groundbreaking insights and innovations in the field of theranostics. Dr. Andreas Jensen, CEO and co-founder of TetraKit Technologies, will be giving a talk on March 24th, highlighting our platform’s inventive application in next-generation theranostics...

NOAR LJUBLJANA

October 11, 2023

NOAR LJUBLJANA

The 4th Working Group and Core Group meeting of the COST Action CA19114 / COST NOAR Astatine – Network for Optimized Astatine-labeled Radiopharmaceuticals is currently underway. The meeting is being held at the Faculty of Pharmacy, University of Ljubljana in Slovenia, from October 9th to 11th, 2023. Stay tuned for updates on the latest developments in the..

Highlight lecture

September 12, 2023

Highlight lecture

Today at #EANM23 in Vienna, Dr. Umberto Battisti presented our data and findings as an EANM-highlighted lecture. We are grateful for the opportunity to show our data to the scientific community dedicated to this field.Please reach out if you want to hear more about our platform technology.#Radiotheranostics #TetraKitTechnologies

Highlight at EANM 23

September 9, 2023

Highlight at EANM 23

Thank you European Association of Nuclear Medicine (EANM) for choosing our talk as a highlight session for this year. You are invited to the Tuesday morning session, where Dr. Umberto Maria Battisti will present our universal labeling platform and its application to develop radiopharmaceuticals labeled with 18F and 211At. The talk will take place on Tuesday, September 12th, from..

EANM 23

September 7, 2023

EANM 23

We are pleased to announce that Dr. Umberto Maria Battisti, the COO and co-founder of TetraKit Technologies, will be speaking at the European Association of Nuclear Medicine (EANM) 23. During the speech, he will highlight the inventive application of our platform in creating next-generation theranostics with the use of 211At.We are excited to have you join us on..

EANM Vienna

August 11, 2023

EANM Vienna

TetraKit Technologies is pleased to announce our participation in the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna from September 09-13, 2023. We are particularly excited to highlight that Dr. Umberto Battisti will deliver a talk on how our platform can be used to synthesize theranostics using 211At.*Please note that Dr. Battisti’s presentation is..

Career Opportunity

July 26, 2023

Career Opportunity

Exciting Opportunity! TetraKit Technologies is currently seeking a Medicinal Chemist/Radiopharmaceutical Specialist. Let’s shape the future together! medicinalchemistry #radiopharmaceuticals #wearehiring

ISRS

May 20, 2023

ISRS

We are delighted to announce that our distinguished Chief Scientific Officer, Dr. Matthias Herth, will attend the 25th International Society for Radiopharmaceutical Sciences (ISRS) conference in beautiful Hawaii. The ISRS conference, renowned for fostering innovation and collaboration, is an ideal platform for presenting our pioneering work and engaging with fellow industry thought leaders. We eagerly anticipate..

BioEquity

May 10, 2023

BioEquity

Our COO, Umberto Maria Battisti, will attend the 23rd annual @BioEquity conference in Dublin, Ireland! Umberto’s participation in BioEquity Europe 2023 highlights our commitment to innovation and growth. During the conference, he will seek new partnerships, discuss the latest advancements in biotechnology, and share insights into our company’s strategy for sustained success. We invite you to..

Noar 2

May 8, 2023

Noar 2

We’re excited to announce that TetraKit will attend the 2nd Annual Global Meeting COST NOAR Astatine in Coimbra, Portugal, from May 9-11, 2023! This event will bring together academics and industry experts to discuss the latest developments in targeted alpha therapy using astatine-211. Our CEO, Andreas Ingemann Jensen, and CSO, Matthias Herth, represent TetraKit at this global conference. They look..

Happy Easter!!

April 9, 2023

Happy Easter!!

Hoppin’ into an enjoyable and happy Easter 🐣 🐇

EMIM 2023

March 16, 2023

EMIM 2023

Our Chief Scientific Officer, Matthias Herth, is attending the 18th European Molecular Imaging Meeting #EMIM2023 this week in Salzburg, Austria. As one of the major events in molecular imaging, EMIM brings together experts from various disciplines to share their latest research findings and network with peers. We are proud to have Dr. Herth represent Tetrakit Technologies at this important event...

🎉 Exciting News Alert! 🎉

March 16, 2023

🎉 Exciting News Alert! 🎉

We are proud to announce that Tetrakit Technologies has officially joined the prestigious Venture House at BioInnovation Institute! 🏢🔬 This is a significant milestone for our team, and we couldn’t be happier to be part of such an inspiring ecosystem of innovative biotech and life sciences startups. 🌐 A big thank you to the entire..

Welcome, Nadia!

March 15, 2023

Welcome, Nadia!

A warm welcome to our newest team member, Nadia. With experience in organic and biomolecular chemistry, Nadia brings knowledge and expertise to our team. Nadia is part of our collaboration with the University of Copenhagen for the development of theranostics targeting the neuropeptide Y1 receptor. Sure, I graduated from the Technical University of Denmark with..

1st anniversary in the BII community

March 2, 2023

1st anniversary in the BII community

Dear Connections, We are thrilled to announce that we are celebrating our 1st anniversary as a Venture Lab startup at BioInnovation Institute! It has been an incredible journey filled with challenges and triumphs, and we are grateful for the opportunity to share it with you all. Looking back on the past year, we are amazed at..

TAT12

February 24, 2023

TAT12

Tetrakit Technologies will be heading to Cape Town, South Africa, for TAT-12, where we will partake in a cutting-edge symposium featuring the latest advancements in targeted alpha therapy. This is an excellent opportunity to network with colleagues from around the globe. Feel free to reach out if you would like to meet us. Contact Andreas for more..

Bio€quity, Dublin

February 13, 2023

Bio€quity, Dublin

The premier international gathering place in Europe for financial power players and biopharma executives to connect with burgeoning biotechnology companies.

BioSeed 2023 in London

January 20, 2023

BioSeed 2023 in London

Our CEO, Andreas Jensen, will present at BioSeed in London, UK. Please reach us if you are interested in learning more about our universal labelling platform for theranostics and how it can be applied in your drug development programs. Schedule a meeting with Andreas Ingemann Jensen, PhD Pharm, by contacting him directly.See you on Monday!

Happy New Year 2023 💫

December 31, 2022

Happy New Year 2023 💫

As we start a new year, it is a time for reflection and setting new goals. The new year is a chance to leave the past behind and look toward the future with hope and determination. It is an opportunity to start fresh and make positive changes in our lives. I hope that this new..

Ph.D. Fellowship

December 9, 2022

Ph.D. Fellowship

We are happy to announce a Ph.D. fellowship collaboration with Dept. of Drug Design and Pharmacology (ILF), University of Copenhagen. Welcome to apply via the Faculty of Health and Medical Sciences, https://healthsciences.ku.dk/#university #collaboration #health #phd

Radiograf Rådet

November 29, 2022

Radiograf Rådet

This year’s Nobel Prize in chemistry prompted the Danish Newspaper Radiograf Rådet to publish a story about the academic research of Dr. Matthias Herth, our very own CSO, using click chemistry. Check it out (in Danish only) 😊 https://lnkd.in/eddXebf2 #clickchemistry #positronemissiontomography #radiotherapy

Supply At-211

November 22, 2022

Supply At-211

We are pleased to announce an agreement with Rigshospitalet (The National Hospital of Denmark), Department of Clinical Physiology, Nuclear Medicine & PET to supply us with astatine-211 (At-211) for our development programs. #hospital #medicine #TAT #alphatherapy #alphaisotopes

TRIMT and TETRAKIT

October 10, 2022

TRIMT and TETRAKIT

#TRIMT and #TETRAKIT are joining forces to develop 18F-Flutrahexin based on #Nobel Prize awarded #technology. Read more in the press release. About TRIMT   TRIMT GmbH is a clinical-stage company developing novel radiopharmaceuticals to diagnose and treat life-threatening diseases. The company was founded in early 2021 in Radeberg near Dresden (Germany). TRIMT holds a worldwide exclusive license for various new radioligands..

ZEIT ONLINE

October 6, 2022

ZEIT ONLINE

As an international expert in click chemistry, Dr. Matthias Herth, our CSO at TetraKit Technologies, was asked by ZEIT ONLINE to comment on this year’s Nobel Prize winners in Chemistry. #future #technology #chemistry #drugdevelopment Read more about this fascinating new technology with incredible potential for future drug development:https://lnkd.in/e7nUAePe

Click chemistry

October 6, 2022

Click chemistry

Congrats to the Nobel Prize winners, Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless “for developing click chemistry and bioorthogonal chemistry.” TetraKit Technologies concurs with this outstanding decision of the Nobel Prize Committee. Click chemistry is also the core of our TetraKit platform, with broad application in pretargeting or drug delivery strategies. The Noble Prize homepage..

Nordic Life Science Days

October 6, 2022

Nordic Life Science Days

TetraKit Technologies is pitching to the international investor community at Nordic Life Science Invest as one of the rising stars 🌟 #nlsdays #nlsinvest #lifescience #radiopharmaceuticals

iSRS conference in Nantes (France)

May 21, 2022

iSRS conference in Nantes (France)

TetraKit will be attending the iSRS conference in Nantes (France), next week. Please reach out, if you would like to meet with us. https://lnkd.in/dxP4exxb Reference

1st Cost-Noar Open Meeting

May 9, 2022

1st Cost-Noar Open Meeting

Our CEO and CSO want to thank the organisers from the 1st Cost-Astatine-211 Noar Open Meeting in Gothenburg for a great meeting. We are looking forward to see further progress in the 211At world. https://lnkd.in/d8-bAZ3p Reference

Wrapping up EANM 2024

October 25, 2021

Wrapping up EANM 2024

Wrapping up an inspiring week at European Association of Nuclear Medicine (EANM) 2024! Proud of the Tetrakit team’s contributions to the advancement of nuclear medicine: “Novel FAPi dimers labeled via tetrazine ligation” – Dr. Marcel Martin presented our latest research using the click chemistry-based TetraKit platform, focusing on radioligand therapy for FAPi dimers. “Pre-targeting Approach:..